Comparative Pharmacology
Head-to-head clinical analysis: DEMULEN 1 35 28 versus MODEYSO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMULEN 1 35 28 versus MODEYSO.
DEMULEN 1/35-28 vs MODEYSO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial receptivity.
The mechanism of action of MODEYSO (elacestrant) is not fully elucidated. Elacestrant is an estrogen receptor antagonist that binds to estrogen receptor alpha (ERα) and degrades it, inhibiting estrogen-mediated signaling and tumor growth in ER-positive breast cancer.
One tablet (contains 1 mg ethynodiol diacetate and 35 mcg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo or no tablets.
400 mg orally once daily with food
None Documented
None Documented
Ethinyl estradiol: 17.4 ± 5.6 h (terminal); norethindrone: 10.9 ± 1.6 h (terminal); clinically, steady-state achieved within 5-7 days.
Terminal half-life approximately 6 days (range 4–10 days) in healthy subjects; supports weekly dosing interval
Renal 50% (metabolites), fecal 50% (biliary elimination of conjugates).
Renal excretion unchanged: <1%; biliary/fecal elimination: >99% as unchanged drug
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive